SMAD4 loss enables EGF, TGFβ1 and S100A8/A9 induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells

Epidermal Growth Factor (EGF) receptor overexpression, KRAS, TP53, CDKN2A and SMAD4 mutations characterize pancreatic ductal adenocarcinoma. This mutational landscape might influence cancer cells response to EGF, Transforming Growth Factor β1 (TGFβ1) and stromal inflammatory calcium binding proteins...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Moz, Stefania, Basso, Daniela, Bozzato, Dania, Galozzi, Paola, Navaglia, Filippo, Negm, Ola H., Arrigoni, Giorgio, Zambon, Carlo-Federico, Padoan, Andrea, Tighe, Paddy, Todd, Ian, Franchin, Cinzia, Pedrazzoli, Sergio, Punzi, Leonardo, Plebani, Mario
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342525/
https://ncbi.nlm.nih.gov/pubmed/27655713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12068
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak